Our Technology
Gamma Vaccines is an early stage company developing innovative technology to produce broad spectrum vaccines against a variety of human and animal viruses, in order to reduce disease burden and reduce the risk of pandemic outbreaks.
A GLOBAL PROBLEM
Addressing viral infections
Viral infections present one of the most serious challenges to global health of our time. Recurring seasonal flu, COVID and other infections cause millions of deaths, dramatic impacts on quality of life, and extreme economic losses.
More alarming is the potential for future pandemics, through zoonotic diseases arising because of viral mutations and demographic changes in human behaviours. Because our vaccines have the potential to produce broad spectrum protection, they have the potential to prevent or greatly ameliorate future pandemics.
GammaFlu® is being developed as a broader-spectrum flu vaccine designed to give better immunity to seasonal influenza strains and increased protection against future influenza pandemics. We are also pursuing research and development of vaccines for other important human and animal viruses, such as SARS-CoV2, Chikungunya, and NDV. Our propriety product “GammaFlu®” can act as an adjuvant to co-administered vaccines, allowing the development of highly effective and commercially valuable combination vaccines.
THE SCIENCE
A new way
to create vaccines
Our vaccines are based on highly purified and/or genetically modified strains of viruses grown either in eggs or in cell culture. These viral strains are inactivated by exposure to high energy photons, creating inactivated viral vaccines that produce robust, broad-spectrum immunity without using adjuvants.
The photon exposure inactivation process provides an advantage over other inactivation methods because it maintains the structure of the virus leading to effective induction of both humoral and cell-mediated immunity. This is in contrast to current chemically inactivated whole virus vaccines, which cannot induce T cell responses. The role of T cell responses in providing cross-protection against pandemic influenza is well documented in literature.
Gamma Vaccines portfolio
GammaFlu
Our lead vaccine candidate. A vaccine against seasonal flu using our patented photon inactivation process to produce effective broad spectrum protection against influenza A and influenza B infections.
Chikungunya vaccine
Under licence, we are commercialising a vaccine for Chikungunya, a viral disease spread by mosquitos and which causes severe arthritic joint inflammation.
GammFlu-COVID
A vaccine candidate that will provide enhanced protection against COVID and influenza infections by combining an existing vaccine for COVID with our GammaFlu vaccine. This exploits the ability of GammaFlu to enhance the effectiveness of other vaccines when given in combination. The same technology can potentially be used with a variety of other vaccines.
NDV
A vaccine for Newcastle Disease, an infection in poultry which causes large economic losses to the poultry and egg producing industries. We are researching the potential to combine this with GammaFlu, to provide protection in chickens against bird flu as well as NDV.
RESEARCH